Retina Macula Institute Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01449682
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

ozurdex (1 trial)

Drugs in Phase 2 Trials (4)

bevacizumab (avastin) (1 trial)

ico-007 (1 trial)

ranibizumab (lucentis) (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 2)

Edema (Phase 2)

Macular Edema (Phase 3)

Retinal Diseases (Phase 2)

Retinal Vein Occlusion (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5